Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer
- PMID: 14708410
- DOI: 10.1177/147323000303100601
Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer
Abstract
This study compared the efficacy of an H2-receptor antagonist (H2RA)- and a proton-pump inhibitor (PPI)-based triple regimen for the eradication of Helicobacter pylori infection. Chinese patients with H. pylori-associated gastritis or peptic ulcer were randomized to receive the H2RA-based triple regimen (20 mg famotidine, 1.0 g amoxicillin and 0.4 g metronidazole) or the PPI-based triple regimen (20 mg omeprazole, 1.0 g amoxicillin and 0.4 g metronidazole) both twice daily for 1 or 2 weeks. Successful eradication of H. pylori was determined by the 13C-urea breath test and gastric mucosa histology at least 4 weeks after completion of antibiotic therapy. Eradication rates were 56.0% and 76.9% for the 1-week H2RA- and PPI-based triple regimens, respectively, and 81.6% and 82.1% for the 2-week regimens, respectively. The H. pylori eradication rate for the 2-week H2RA regimen was significantly higher than that for the 1-week regimen, but there were no significant differences between the 1- and 2-week PPI regimens. The two regimens proved equally effective in eradicating H. pylori infection.
Similar articles
-
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.Clin Pharmacol Ther. 1999 Nov;66(5):528-34. doi: 10.1016/S0009-9236(99)70017-2. Clin Pharmacol Ther. 1999. PMID: 10579481
-
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).Arch Intern Med. 2002 Jan 28;162(2):153-60. doi: 10.1001/archinte.162.2.153. Arch Intern Med. 2002. PMID: 11802748 Clinical Trial.
-
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.Eur J Gastroenterol Hepatol. 1994 Dec;6 Suppl 1:S103-7. Eur J Gastroenterol Hepatol. 1994. PMID: 7735924 Clinical Trial.
-
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].Nihon Rinsho. 1999 Jan;57(1):127-33. Nihon Rinsho. 1999. PMID: 10036949 Review. Japanese.
-
No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease.Aliment Pharmacol Ther. 1995;9 Suppl 1:39-42. doi: 10.1111/j.1365-2036.1995.tb00782.x. Aliment Pharmacol Ther. 1995. PMID: 7495941 Review.
Cited by
-
Xiao Chai Hu Tang for Peptic Ulcers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Evid Based Complement Alternat Med. 2021 Apr 29;2021:6693677. doi: 10.1155/2021/6693677. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34012475 Free PMC article. Review.
-
Optimum duration of regimens for Helicobacter pylori eradication.Cochrane Database Syst Rev. 2013 Dec 11;2013(12):CD008337. doi: 10.1002/14651858.CD008337.pub2. Cochrane Database Syst Rev. 2013. PMID: 24338763 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical